In this episode of InnoStars Talks, we speak with Milena Argirovic, Country Head at Takeda for Serbia, Albania, North Macedonia, Kosovo, and Montenegro. We explore how a region often seen as “lagging behind” is becoming a testing ground for bold innovation, data-driven solutions, and global partnerships.
👉 Can Big Pharma be truly agile?
👉 Why is Serbia a perfect pilot for the European Health Data Space?
👉 What advice does Milena have for early-stage innovators?
Tune in to hear how Takeda is bridging East and West—and shaping the future of personalised care.
Can technology save lives? In our latest episode of InnoStars Talks with Lehel Ferenczi from GE Healthcare we tell the real story behind AI in diagnostics, treatment, and prediction - and why trust is the final frontier.
From early cancer detection to smarter ultrasound tools, this conversation reveals how data, design, and discipline are reshaping patient care—one algorithm at a time.
How can technology combat the global threat of counterfeit medicines?
Monika Stepanova, CEO and co-founder of Lightly Technologies, shares how her Czech start-up is pioneering a portable solution to detect fake drugs—helping law enforcement agencies and public health authorities tackle a crisis that is rapidly escalating worldwide.
Discover how Lightly Technologies’ patented UV fingerprinting method not only identifies counterfeit substances but also cross-matches drug shipments globally, a breakthrough innovation in forensic analysis. Monika also reflects on the challenges of hardware development, navigating government partnerships, and scaling impact-driven innovation—along with the invaluable support received from EIT Health’s Jumpstarter programme.
How can we prepare future healthcare professionals for a rapidly evolving industry? Dr Rita Rocha, Coordinator of the Innovation and Value Creation Office at NOVA Medical School, shares how the institution is redefining medical education by fostering technology literacy, data analysis, ethical decision-making, and innovation.
Discover how NOVA’s global partnerships—including Harvard Medical School, the Oswaldo Cruz Foundation, and EIT Health—are shaping a new generation of healthcare leaders. Plus, explore the ASSIST Project, which is driving AI-powered medical devices and accelerating start-up technologies from pre-clinical assessment to market entry.
📣 Congratulations to Moodmon, the project led by the Polish company Britenet, an InnoStars partner, for being awarded €1 million in funding through EIT Health’s prestigious Flagship Call. With the support of a distinguished European consortium, they are now set to obtain a CE mark, conduct clinical trials, and showcase its real-world healthcare benefits. Additionally, the team is working on creating a legal framework for AI retraining without the need for full recertification.
Curious about how artificial intelligence is transforming psychiatry?
🎙️Tune in to the latest episode of the InnoStars Talks podcast, where Dr Marlena Sokoł-Szawlowska from the Institute of Psychiatry and Neurology in Warsaw, the innovator behind MoodMon, discusses this AI-powered tool for detecting and managing affective disorders such as depression and bipolar disorder.
🎙️ Join us for the third episode of InnoStars Talks, an engaging podcast series presented by EIT Health in partnership with Emerging Europe! Get ready for insightful discussions with health innovators transforming the medical landscape. 👥 In our latest episode, we speak with Jan Beger of GE Healthcare. Tune in as he talks about why and how to equip healthcare professionals with the skills they need to understand AI and other disruptive technologies.
🎙️ Join us for the second episode of InnoStars Talks, an engaging podcast series presented by EIT Health in partnership with Emerging Europe! Get ready for insightful discussions with health innovators transforming the medical landscape. 👥 In our latest episode, we feature Maurizio Ferrari from SYNLAB Italia. Tune in as he shares his journey and the groundbreaking advancements in diagnostic biomarkers and testing methodologies. Synlab Italy, a key partner in our InnoStars Connect programme, is at the forefront of innovation in the health sector. Their commitment to enhancing diagnostic accuracy and efficiency paves the way for improved patient outcomes. In this episode, you'll learn how Synlab's cutting-edge technologies are significantly impacting healthcare and how they plan to engage in further development phases.
👥 In our first episode, Andrew Wrobel talks with Mate Balazs Kovacs, CEO and co-founder of AIPLabs, about his groundbreaking journey in combating skin diseases with AI-enhanced digital healthcare solutions. AIP Labs, the InnoStars Partner from Hungary is an artificial intelligence development company, which created a digital hospital ecosystem. Its first dermatology module, AIP Derm, is up and running in Spain, Hungary and Slovakia with tens of thousands of users. AIP Labs is unique in that it is not only a developer in the med-tech sector, but also a healthcare service provider. Their systems are extremely user-friendly, as they develop them in close collaboration with doctors, adapting them to their needs. 🔍 Discover how AIP Labs is revolutionising patient care by reducing wait times and enhancing the efficiency of dermatology treatments. This episode is not just about health innovation; it's about shaping the future of healthcare with advanced technologies and compassionate care. 📅 Don’t miss out! Tune in to gain valuable insight and be part of the conversation that’s redefining healthcare.
In this episode, Balázs Fürjes invites to a chat with Professor Krzysztof Klincewicz from the Faculty of Management at Warsaw University.
The discussion, hosted by Andrew Wrobel focuses on the importance of collaborative innovation in boosting innovation in the European Union, particularly in countries with moderate or modest innovation scores.
Don't forget to visit our website at eithealth.eu/in-your-region/innostars/ for more information about our new programmes, calls for proposals and applications and events.
In this episode, Balázs Fürjes invites to a chat with Professor Guido Boella, Vice-Rector for Enterprises at the University of Turin.
The discussion, hosted by Andrew Wrobel focuses on the role of digital innovation hubs in strengthening innovation in the European Union, particularly in countries with moderate or modest innovation scores.
Don't forget to visit our website at eithealth.eu/in-your-region/innostars/ for more information about our new programmes, calls for proposals and applications and events.
When the Covid-19 pandemic hit, health tech stepped up, with what appeared to be 10 years’ worth of innovation occurring in 10 weeks. But, while the pandemic encouraged more partnerships and collaboration in the sector, it has also brought about multiple challenges for start-ups, such as making it more difficult to complete clinical validation through sourcing hardware or delaying the implementation of their go-to-market strategies.
Tamás Békási, RIS Business Creation Manager at the EIT Health InnoStars, spoke with Andrew Wrobel about the current trends in health tech, opportunities and challenges, and offers plenty of advice to future healthcare hackers.
This year a total of 36 teams from all over Europe showcased their budding start-ups in front of a jury of experts and potential investors, competing for a prize pool of 160,000 euros. The flagship programme of the European Institute of Innovation and Technology (EIT), EIT Jumpstarter is a pre-accelerator programme led by EIT Health and involving other EIT Knowledge and Innovation Communities (KICs) with the goal of boosting innovation and entrepreneurship in Central, Eastern and Southern Europe.
In this episode, Balázs Fürjes speaks with Dora Marosvolgyi, EIT Jumpstarter mentor and project manager at EIT Health InnoStars, about the value the programme gives to your entrepreneurs and the innovation it creates.
Don't forget to visit our website at eithealth.eu/in-your-region/innostars/ for more information about our new programmes, calls for proposals and applications and events.
Success in precision medicine depends on accessing high-quality genetic and molecular data that, in conjunction with comprehensive clinical data, can lead to more effective therapies. Although omics data is available on public databases, doctors are not yet able to extract useful value from it owing to its sheer volume and heterogeneity.
While there are solutions to this problem - based on Big Data and Artificial Intelligence - these are mainly designed for specific diseases; this while there are 400 million patients around the globe affected by rare diseases. Kazaam Lab’s solution is an innovative, electronic, passive dosimeter based on a CMOS Floating Gate sensor monolithically implemented on a single chip.
Simona Rombo, an associate professor of computer science at the University of Palermo and one of the founders and the CEO of Kazaam Lab, spoke with Andrew Wrobel about the challenges her start-up has faced and overcome, as well as offering some tips for young researchers developing health solutions.
Spastic hand paralysis is a painfully common problem experienced by patients who have suffered damage to the central nervous system due to a stroke or other causes. These patients are not able to autonomously open their fingers, which significantly impacts quality of life. There are about 20 million people suffering from hand spasticity worldwide, out of which 1.3 million people live in Europe.
Phoenix Orthosis uses an innovative approach to substitute the fingers’ ability to open, while intentionally remaining as discreet as possible. Thus, the paralysed hand can be reintegrated into everyday life which is the most effective route to rehabilitation.
Robert Ackermann, CCO at Phoenix Orthosis, spoke with Andrew Wrobel about the solution, its implementation on the German market and the impact the Covid-19 pandemic has had on the development of the product.
EIT Health Spain has had a particularly fruitful 2020 in terms of health innovation projects.
In this episode, Balázs Fürjes speaks with Cristina Bescos, managing director at EIT Health Spain. Cristina holds a PhD in Biomedical Engineering and has a long career in research and management of large international teams in digital health and healthcare transformation, combining experience from public research institutions and the private sector. They discuss the key success factors and lessons from EIT Health Spain’s collaboration with partners and co-location centres (CLCs).
Don't forget to visit our website at eithealth.eu/in-your-region/innostars/ for more information about our new programmes, calls for proposals and applications and events.
Leg length discrepancy (LLD) is an orthopaedic condition that involves a difference in length between the lower extremities. This is a significant medical problem, and the causes may be various trauma, diseases, deformities of the locomotor system, surgery, growth disorders, neurological illness, and others. Statistics have shown that up to 90 per cent of the population has LLD.
Croatian start-up Cognitus has developed a solution to measure leg length discrepancy and created insoles that can help correct posture and improve the quality of life.
Alan Mutka, one of the founders and chief technology officer at Cognitus Limited, as well as a senior lecturer and research associate at the Rochester Insitute of Technology Croatia, spoke with Andrew Wrobel about his solution, as well as the challenges his start-up has faced.
Mild cognitive impairment (MCI) is a precursor to Alzheimer’s disease (AD), the most common form of dementia. MCI contributes to 60–70 per cent of dementia cases, an illness for which there is currently no cure.However, very early-stage existing therapies can improve and prolong cognitive function.
Neus is a software solution for detecting MCI that combines eye-tracking technology, digitalised neuropsychological tests with an AI-based decision support system.
In this episode, Vida Groznik, one of the co-founders and the CEO of Neus Diagnostics, spoke with Andrew Wrobel about how her team came up with the solution that helps diagnose dementia and other diseases, as well as the challenges her start-up has faced and overcome.
Monitoring the effects that drugs have on liver tissue is one of the primary tests used in the early phases of drug development and toxicological screening. Today, hepatotoxicity is tested either on cell lines (in vitro) or laboratory animals. But the current solutions are not delivering a long-term culture of human primary hepatocytes and are still dependent on cell lines (cancer cells) and animal models.
Czech Inocure’s HepaMATRIX, therefore, delivers a solution to an unmet clinical need — reliable models of liver tissue. The testing of novel drugs, the prevention of the toxic effects of drugs on the liver, knowledge about molecule biotransformation and liver pathologies need reliable models of human hepatic tissues. It is a novel technology enabling a culture of human primary hepatocytes in a better environment. The idea is focused on delivering ready-to-use artificial matrices — microplates with HepaMATRIX membranes - for in vitro production of liver models used in drug development, toxicological screening, basic research of liver diseases and diagnosis of patients with liver diseases.
Inocure’s CEO Matej Buzgo speaks with Andrew Wrobel about his start-up’s path to designing next-generation drug delivery systems and the multiple challenges he faces and offers valuable advice to potential researchers and founders working on innovative health solutions.
Attention-deficit hyperactivity disorder (ADHD) is prevalent in people of all ages. Children and adults with ADHD frequently experience social exclusion as the society around them reacts negatively to their inability to understand and abide by the prevailing “social code”. It is currently estimated that up to five per cent of school-age children are affected by ADHD. The majority of these children will experience problems adapting to the school environment and this may lead to educational underachievement. As a result, as many as 60 per cent of these children may find it difficult to find, and sustain, paid employment after leaving school.
Tully is a wearable device monitoring physiological indicators, helping children with ADHD and their therapists by providing external input for stress and agitation awareness, and by improving the therapist’s ability to gauge a patient's emotional evolution and the efficiency of therapy.
Hyperactivity in ADHD is linked to intellectual challenge and mental strain and manifests mostly during school lessons. The intellectual challenge increases stress and leads to emotional flare-ups. This can happen multiple times a day, interrupting classes and leading to the children’s marginalisation, with severe effects on their development.
Marius Rus, co-founder and CEO of Tully, speaks with Andrew Wrobel about how his #startup helps children recognise and manage emotions and gives valuable tips to potential founders working on health solutions.
Mental health is the main medical area in which routine decision-making for diagnoses and treatment choices is primarily based on clinical interviews and observations. Despite the availability of internationally accepted diagnostic and treatment guidelines, the adherence among clinicians to these standards in mental health is low, what is reflected by high rates of misdiagnosis and mistreatment. The unreliability of psychiatric diagnosis and “hit-or-miss” treatment approach remain serious and core problem.
DocuMental is a unique decision support system, which improves the diagnostic and treatment reliability in mental health by implementing structured and standardized digital workflow, which responds more effectively to the need for better diagnosis, management and outcome, than traditional approach of current mental healthcare systems.
In this episode, Eduard Maron, CEO od DocuMental, spoke with Andrew Wrobel about the challenge he faced as a young psychiatrist and how he created a solution that helps him and his colleagues diagnose mental disorders better.
